快速MRSA鼻部PCR筛查对ICU万古霉素使用的影响
该回顾性准实验研究在613张床位的学术医疗中心67张ICU床中,纳入2017至2019年ICU住院≥24小时且因肺炎经验性使用静脉万古霉素的成人患者,评估药师驱动的MRSA鼻部PCR筛查方案实施前后万古霉素使用时长变化。结果显示万古霉素中位疗程由2.59天降至1.44天,约减少1.00天(P<0.01),且万古霉素血药浓度监测次数更少、急性肾损伤发生率更低。
要点
- 药师驱动的MRSA鼻部PCR筛查可缩短疑似肺炎ICU患者经验性万古霉素疗程约1天。
- 该方案实施后万古霉素血药浓度监测次数显著减少,急性肾损伤发生率更低。
- 除急性肾损伤和监测次数外,两组其他次要结局相似。
核心结论
- 实施药师驱动的MRSA鼻部PCR筛查与疑似肺炎危重患者万古霉素疗程缩短及血药浓度监测次数减少相关。
研究设计与样本
- 回顾性准实验研究,在613张床位、67张ICU床的学术医疗中心开展,最终分析纳入418例患者。
- 纳入2017至2019年ICU住院≥24小时且因肺炎经验性开始静脉万古霉素的成人患者。
- 主要干预为实施MRSA鼻部PCR筛查方案,主要结局为经验性万古霉素治疗时长。
主要发现
- 万古霉素中位疗程在方案前组为2.59天,方案后组为1.44天,约减少1.00天(P<0.01)。
- 方案后组万古霉素血药浓度监测次数显著少于方案前组。
- 方案后组急性肾损伤发生率更低,且万古霉素血药浓度监测次数更少(尽管已实施基于AUC的万古霉素给药)。
- 其他次要结局两组相似。
临床怎么用
- 对疑似肺炎的ICU患者,可考虑实施药师驱动的MRSA鼻部PCR筛查以辅助尽早停用经验性万古霉素。
- 该策略可能减少万古霉素血药浓度监测次数并降低急性肾损伤风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the impact of a pharmacist-driven methicillin-resistant Staphylococcus aureus (MRSA) nasal polymerase chain reaction (PCR) screen on vancomycin duration in critically ill patients with suspected pneumonia. METHODS: This was a retrospective, quasi-experimental study at a 613-bed academic medical center with 67 intensive care beds. Adult patients admitted to the intensive care unit (ICU) between 2017 and 2019 for 24 hours or longer and empirically started on intravenous vancomycin for pneumonia were included. The primary intervention was the implementation of a MRSA nasal PCR screen protocol. The primary outcome was duration of empiric vancomycin therapy. Secondary outcomes included the rate of acute kidney injury (AKI), the number of vancomycin levels obtained, the rate of resumption of vancomycin for treatment of pneumonia, ICU length of stay, hospital length of stay, the rate of ICU readmission, and the rate of in-hospital mortality. RESULTS: A total of 418 patients were included in the final analysis. The median vancomycin duration was 2.59 days in the preprotocol group and 1.44 days in the postprotocol group, a reduction of approximately 1.00 day (P < 0.01). There were significantly fewer vancomycin levels measured in the postprotocol group than in the preprotocol group. Secondary outcomes were similar between the 2 groups, except that there was a lower rate of AKI and fewer vancomycin levels obtained in the postprotocol group (despite implementation of area under the curve-based vancomycin dosing) as compared to the preprotocol group. CONCLUSION: The implementation of a pharmacist-driven MRSA nasal PCR screen was associated with a decrease in vancomycin duration and the number of vancomycin levels obtained in critically ill patients with suspected pneumonia.
引用
- Diep C, Meng L, Pourali S, et al. Effect of rapid methicillin-resistant Staphylococcus aureus nasal polymerase chain reaction screening on vancomycin use in the intensive care unit. Am J Health Syst Pharm. 2021. PMID: 34297040. doi:10.1093/ajhp/zxab296
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。